Evidence map›Paper›PMID 37056242›Full record

ArticleBio-protocol2023

Preparation and Characterization of IL-22 mRNA-loaded Lipid Nanoparticles.

Zahra Alghoul, Junsik Sung, Kenji Wu, Gianfranco Alpini, Shannon Glaser, Chunhua Yang, Didier Merlin

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bio-protocol, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zahra AlghoulInstitute for Biomedical Sciences, Digestive Diseases Research Group, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.
Junsik SungInstitute for Biomedical Sciences, Digestive Diseases Research Group, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.
Kenji WuInstitute for Biomedical Sciences, Digestive Diseases Research Group, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.
Gianfranco AlpiniDivision of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, 46220, USA.
Shannon GlaserDepartment of Medical Physiology, Texas A&M University School of Medicine, Bryan, TX, 77807, USA.
Chunhua YangInstitute for Biomedical Sciences, Digestive Diseases Research Group, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.
Didier MerlinInstitute for Biomedical Sciences, Digestive Diseases Research Group, Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, USA.
Veterans Health Administration · USGeorgia State University · US

Funding

Fecal exosomes as a source of miRNA biomarkers for diagnosing the degree of colitis and as a drug delivery system to reduce colitisR01DK116306 · NIDDK · GEORGIA STATE UNIVERSITY · PI DENNING, TIMOTHY L, GEWIRTZ, ANDREW T · 2017 to 2020
$1.8M
Novel Therapeutic Approaches For Treatment of Intestinal InflammationR01DK107739 · NIDDK · GEORGIA STATE UNIVERSITY · PI DENNING, TIMOTHY L, MERLIN, DIDIER · 2017 to 2020
$1.4M
Role of Sensory Innervation in High Fat Diet-Induced HepatotoxicityR01DK132891 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI ALPINI, GIANFRANCO D, FRANCIS, HEATHER L · 2022 to 2023
$1.1M
Autocrine/Paracrine Regulation of Intrahepatic Bile Duct GrowthI01BX000574 · VA · RLR VA MEDICAL CENTER · PI ALPINI, GIANFRANCO D · 2009 to 2022
–
Small intestinal PepT1 expression plays a critical role in maintaining intestinal homeostasis and in shaping the gut microbiotaI01BX002526 · VA · VETERANS HEALTH ADMINISTRATION · PI MERLIN, DIDIER · 2014 to 2024
–
BLR&D Research Career Scientist AwardIK6BX004601 · VA · RLR VA MEDICAL CENTER · PI ALPINI, GIANFRANCO D · 2019 to 2025
–
BLRD VA I01 BX000574BLRD VA I01 BX002526BLRD VA IK6 BX004601NIDDK NIH HHS R01 DK107739NIDDK NIH HHS R01 DK116306NIDDK NIH HHS R01 DK132891
6 · The paper itself

Abstract

Interleukin-22 (IL-22) has been demonstrated as a critical regulator of epithelial homeostasis and repair; it showed an anti-inflammatory effect against ulcerative colitis. Local microinjection of IL-22 cDNA vector has been shown to be effective in treating ulcerative colitis in mouse models. However, microinjection comes with multiple technical challenges for routine colon-targeted drug delivery. In contrast, oral administration can get around these challenges and provide comparable efficacy. We showed in previous studies that oral administration of new lipid nanoparticles (nLNP)-encapsulated IL-22 mRNA targets the colon region and efficiently ameliorates colitis. This protocol describes the details of preparing and characterizing the nLNP-encapsulated IL-22 mRNA using three major lipids that mimic the natural ginger-derived nanoparticles. It provides an nLNP platform that can be used to orally deliver other types of nucleic acids to the colon.

Indexed as

Drug deliveryInterleukin-22Intestinal inflammationLipid nanoparticlesUlcerative colitis

Identifiers

PMID37056242
PMCPMC10086544
OpenAlexW4362569381

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.